Compare iShares MSCI Taiwan ETF (EWT) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Taiwan ETF vs Neurocrine Biosciences Inc — how do they compare? iShares MSCI Taiwan ETF trades at $114.88 (market cap $12.74B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.36B). The key difference: iShares MSCI Taiwan ETF and Neurocrine Biosciences Inc are close in size by market cap, and iShares MSCI Taiwan ETF is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Taiwan ETF for 52 Days and Neurocrine Biosciences Inc for 23 Days on average.
| EWT | NBIX | |
|---|---|---|
Market Cap | $12.74B | $14.36B |
Volume | 8,470,920 | 1,237,180 |
Sector | Broad Market / Factor | Health |
52-Week High | $118.00 | $185.50 |
52-Week Low | $60.03 | $123.10 |
Typical Hold Time | 52 Days | 23 Days |
Enterprise Value | — | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWT trades at $116.24, down 1.16% today, with a bullish technical outlook supported by moving averages. The ETF remains heavily concentrated in Taiwan's semiconductor sector, particularly TSMC, benefiting from AI-driven demand. Recent news highlights continued US-Taiwan economic cooperation and institutional buying interest.
The outlook remains positive given Taiwan's strategic position in AI supply chains, though geopolitical tensions pose significant risks. Valuation appears reasonable for tech exposure, but investors must weigh semiconductor cyclicality against long-term growth potential in artificial intelligence infrastructure.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MSCI Taiwan ETF
EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.
Read more on EWT →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
